Overview

Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:
0

Participant gender:
All

Summary

Chidamide combines with VP-16 and methylprednisolone in HLH

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Beijing Friendship Hospital

Treatments:

Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate

Criteria

Inclusion Criteria:Meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria;
patients were diagnosed with EBV associated HLH (EBV-HLH) and lymphoma associated HLH.Age
≥18 years old, gender is not limited. Serum creatinine ≤ 1.5 times normal；NT-proBNP ≤
normal；Informed consent obtained.

-

Exclusion Criteria: Active bleeding of the internal organs or patients with new thrombotic
diseases；Allergic to Chidamide and etoposide；Participate in other clinical research at the
same time；HIV , HBV and HCV infected patients (HIV antibody positive)；History of QT
interval prolongation, atrioventricular block, ventricular tachycardia, coronary
atherosclerotic heart disease；Pregnant or lactating women and patients of childbearing age
who refuse to take appropriate contraceptive measures during this trial. If the patient was
male, he refused to use adequate contraceptive methods or donate semen during the study
period and within 3 months after receiving the last cycle of drug study；patients judged by
the investigator to be unsuitable to participate in this study.

-